Dana-Farber Research News 06.01.2026 - Summary - MDSpire

Dana-Farber Research News 06.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 - 15.

  • By

  • June 1, 2026

  • 38 min

Share

Objective:

Highlight recently published research by Dana-Farber faculty from May 1 - 15.

Key Findings:
  • Connexin-43 (Cx43) plays a critical role in hematopoietic stem cell function and metabolic regulation.
  • Three evolutionary patterns of malignant B cells in Waldenström macroglobulinemia were identified, influencing treatment response.
  • PSMD1 is overexpressed in multiple myeloma and targeting it can reduce tumor growth and overcome drug resistance.
  • Personalized cancer neoantigen vaccines offer a targeted approach to immunotherapy.
Interpretation:

The studies provide insights into cellular mechanisms affecting treatment responses and highlight potential therapeutic targets.

Limitations:
  • The studies may have limited generalizability due to specific patient populations.
  • Further validation of findings in larger cohorts is necessary.
Conclusion:

The research underscores the importance of understanding cellular dynamics and targeting specific pathways in cancer treatment.

Original Source(s)

Dana-Farber Research News 06.01.2026

  • by

  • June 1, 2026

Related Content

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

Chemoradiation after chemotherapy for metastatic cervical cancer can provide chemo-free time

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial